NCT07385079 2026-02-03
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
3 trialsNCT07373990 2026-01-28
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06682442 2025-04-20
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Phase NA Recruiting